GT BIOPHARMA, INC. Debt Securities, Available-for-sale, Unrealized Gain (Loss)
GT BIOPHARMA, INC. (GTBP) reported Debt Securities, Available-for-sale, Unrealized Gain (Loss) of $7.86 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedGainLoss · last filed 2025-02-21
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2024-03-31 was $7.86M, a 55.99% decline year-over-year.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-12-31 was -$473.00K.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-09-30 was -$1.84M.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized gain (loss) for the quarter ending 2023-06-30 was -$2.65M.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2023 was $12.89M, a 18.98% increase from fiscal 2022.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2022 was $10.84M, a 52.91% decline from fiscal 2021.
- GT BIOPHARMA, INC. debt securities, available-for-sale, unrealized gain (loss) for fiscal 2021 was $23.01M.
| Period end | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2024-03-31 | $7.86M 10-Q · filed 2024-05-15 | $7.38M derived: sum of 2 quarters · filed 2025-02-21 | $5.54M derived: sum of 3 quarters · filed 2025-02-21 | $2.90M derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-12-31 | -$473.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$2.31M derived: sum of 2 quarters · filed 2025-02-21 | -$4.96M derived: sum of 3 quarters · filed 2025-02-21 | $12.89M 10-K · filed 2025-02-21 |
| 2023-09-30 | -$1.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | -$4.49M derived: sum of 2 quarters · filed 2023-11-01 | $13.37M 10-Q · filed 2023-11-01 | $5.88M derived: sum of 4 quarters · filed 2024-03-26 |
| 2023-06-30 | -$2.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $15.21M 10-Q · filed 2023-08-07 | $7.72M derived: sum of 3 quarters · filed 2024-03-26 | |
| 2023-03-31 | $17.85M 10-Q · filed 2023-05-15 | $10.37M derived: sum of 2 quarters · filed 2024-03-26 | ||
| 2022-12-31 | -$7.48M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $10.84M 10-K · filed 2024-03-26 | ||
| 2022-09-30 | $18.32M 10-Q · filed 2022-10-31 | |||
| 2021-12-31 | $23.01M 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |